Aller au contenu principal
Accès ouvert déclaré 2025 article

Brief Report: Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results From IMPAACT 2010/VESTED

0Citations signalées, ce qui n’est pas une note de qualité
21Institutions déclarées
8Pays d’affiliation déclarés

Rattachement africain : us, Zambie, Zimbabwe, Ouganda, Botswana, Afrique du Sud, Tanzanie, in. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: Limited information is available on breast milk transfer and subsequent infant systemic exposure to dolutegravir (DTG), tenofovir alafenamide (TAF), and tenofovir (TFV). We evaluated concentrations of DTG, TAF, and TFV in maternal and infant plasma and breast milk from participants of International Maternal Pediatric Adolescent AIDS Clinical Trials 2010, a clinical trial that enrolled women initiating either a DTG-containing or an efavirenz-containing antiretroviral treatment regimen during pregnancy. METHODS: Time-matched postpartum maternal and infant samples were collected at 6 weeks postpartum. Validated assays quantitated concentrations of DTG, TAF, and TFV. Relative infant dose was estimated using an average milk intake of 150 mL/kg/d and observed breast milk concentrations. RESULTS: Data were available from 192 postpartum lactating women and their breastfed infants. Median maternal plasma concentrations of DTG, TAF, and TFV were 2810, 0.0, and 96 ng/mL, respectively. For DTG, median [interquartile range (IQR)] concentrations in breast milk and infant plasma were 91 ng/mL (67-123) and 69 ng/mL (41-95), respectively. TAF was below the quantitative limit (BQL) in nearly all breast milk and infant plasma samples. For TFV, median (IQR) concentrations in breast milk were 8 ng/mL (6-12), and nearly all infant plasma samples were BQL. The median RIDs of DTG, TAF, and TFV from breastfeeding were 1.9%, 0.00%, and 0.03%, respectively. CONCLUSIONS: Breast milk transfer of DTG, TAF, and TFV is low and results in minimal systemic exposure in breastfed infants. The clinical relevance of infant exposure to low concentrations of these antiretrovirals-particularly DTG-is unknown but should be considered in the context of the risk of drug resistance in infants who acquire HIV.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Brief Report: Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results From IMPAACT 2010/VESTED
Date Crossref
01/03/2026
Éditeur
Ovid Technologies (Wolters Kluwer Health)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV-related health complications and treatments

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.